C4 Therapeutics, Inc. (CCCC)
Biological Products, (No Diagnostic Substances)
Latest Price
$3.48
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
1.86
P/B Ratio
1.87
Institutional Ownership
71.7% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| MORGAN STANLEY | 9.07M | $23.0M | 8.72% | +90.7K | 2026-03-31 |
| RA CAPITAL MANAGEMENT, L.P. | 8.00M | $21.0M | 7.69% | -- | 2026-03-31 |
| Bain Capital Life Sciences Investors, LLC | 7.17M | $18.0M | 6.89% | -- | 2026-03-31 |
| Lynx1 Capital Management LP | 7.00M | $18.0M | 6.73% | -99.2K | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.86M | $10.0M | 3.71% | -- | 2026-03-31 |
| Soleus Capital Management, L.P. | 3.80M | $10.0M | 3.66% | -- | 2026-03-31 |
| WASATCH ADVISORS LP | 2.96M | $7.0M | 2.85% | -1.38M | 2026-03-31 |
| CITADEL ADVISORS LLC | 2.59M | $6.0M | 2.49% | +2.09M | 2026-03-31 |
| RENAISSANCE TECHNOLOGIES LLC | 2.46M | $6.0M | 2.37% | +859.2K | 2026-03-31 |
| GOLDMAN SACHS GROUP INC | 2.39M | $6.0M | 2.29% | +1.30M | 2026-03-31 |